Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
Robert M. Neer(Brigham and Women's Hospital), Bruce Mitlak(Radius Health (United States)), Johan Halse(Oslo University Hospital), Ewa Marcinowska-Suchowierska, Jean‐Yves Reginster(King Saud University), Jorma Salmi(Tampere University Hospital), Harry K. Genant(University of California, San Francisco), Dan Mellström(Sahlgrenska University Hospital), Richard L. Prince(Edith Cowan University), Sophia Ish‐Shalom(Rambam Health Care Campus), Ouhong Wang(Eli Lilly (United States)), Erik Fink Eriksen(Osteoporosis Canada), Erik S. Oefjord, Claude D. Arnaud(Mayo Clinic), Andrzej Sawicki, Henk Mulder, Anthony B. Hodsman(Western University), Gregory Gaich(Eli Lilly (United States)), José Zanchetta(Universidad del Salvador)
Cited by 4,591
Related Papers
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2012|2.9k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2018|1.8k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k
RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 FOR TREATMENT OF OPEN TIBIAL FRACTURES
|Journal of Bone and Joint Surgery|2002|1.3k